Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cipher Mining Inc (CIFR) vs Eli Lilly And Co (LLY) Price & Performance

Cipher Mining IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Cipher Mining Inc vs Eli Lilly And Co — how do they compare? Cipher Mining Inc trades at $17.86 (market cap $7.14B), while Eli Lilly And Co trades at $1,221 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 151.3× Cipher Mining Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.

CIFRLLY
Market Cap
$7.14B$1.08T
Sector
Basic MaterialsHealth
52-Week High
$29.18$1.24K
52-Week Low
$4.72$639.43
Enterprise Value
$11.90B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cipher Mining Inc

CIFR trades at $17.87, up 9.43% in 24 hours, but remains in a bearish technical trend with significant fundamental challenges. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue of $191 million and a net loss of $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in transitioning from Bitcoin mining to AI data center operations.

The outlook hinges on successful execution of its AI infrastructure pivot, but high valuation ratios and persistent losses pose substantial risks. Near-term support lies at $16, while resistance is at $18. Investor sentiment is divided between optimism over AI contracts and concerns over cash burn and mining dependency.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cipher Mining Inc

Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.

Read more on CIFR

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY